Medical news network February 28th 2017 edition of health insurance directory new varieties from the quantitative point of view, Chinese medicine is undoubtedly the biggest winner, which contains a large number of exclusive varieties (165), from the procurement perspective, will undoubtedly occupy the advantage in the market access in the future.
2017 edition of the new varieties of Medicare catalog exclusive varieties
However, due to the special form of traditional Chinese medicine, the medical mechanism is not clear, the lack of evidence-based support of modern medicine, there is controversy in clinical use. The function of Chinese traditional medicine in a wide range of seemingly, but not really able to open the door of the hospital, many Chinese medicine market positioning is to build up a so-called general medication, just wishful thinking, most varieties are still used in a certain field, dispersion, narrow. Therefore, a large number of exclusive varieties can not be made?.
However, for traditional Chinese medicine injections, this is indeed a large variety of emerging, especially the 04 edition, the 09 edition of the health insurance directory, the achievements of some heavy varieties. If Kanion pharmaceutical Reduning, into the health insurance but before the 100 million sales, but into the health insurance directory after sales soared to 1 billion 400 million yuan. In addition, Addie, and so on have good performance.
However, compared to the 09 version and 17 version of the catalog, we found that traditional Chinese medicine injection has not changed much, just out of the 2, but in 3, the overall increase of 1, a total of 49 (originally Gastrodin Injection chemicals, before the wrong in the part of Chinese Medicine)
Before the injection of traditional Chinese medicine in the medical insurance directory so stable, a lot of people before hanging a heart finally landed.
However, the new version of the catalog of traditional Chinese medicine injections are also an unprecedented increase in the 49 varieties of the restrictions made in the 39.
Old and new version of the two edition of Chinese medicine injection insurance catalog remarks contrast
For example, use only 2 medical institutions above the level of the market, many deep base, especially the base drug varieties is a fatal blow (do not know the health department and so do the impression of basic medicine suffered).
In addition, clear restrictions on disease severity, scope, specific usage, which is for the use of drugs has caused no small obstacle: no Medicare reimbursement or pay ratio is too large, no matter from the medical institution or the patient's perspective, will be the loss of some prescription. Coupled with the strict implementation of the disease in the future, then followed by the limitations of clinical pathway management and even exclusion.
Varieties with no restrictions may have a comparative advantage. For example, Qingre injection, Yinhuang Injection, etc., or to seize the market share of similar species.
Gastrodin Injection mentioned above, from the traditional Chinese medicine to western medicine directory, there are two benefits:
Will not be as effect of traditional Chinese medicine clinical use, will not be repeated as a traditional Chinese medicine effect of drugs reimbursement, will not be treated as Chinese medicine adjuvant into the directory.
Clinical use of the drug is generally not more than a group of traditional Chinese medicine injections, if the list of Chinese medicine may be used as a medicine to invigorate the circulation of blood stasis, or multiple groups of traditional Chinese medicine injections combined with the impact of Medicare reimbursement;
And in the list notes without restrictions, the future may be able to erupt.
For example, tanshinone II A, gastrodin and are the same as chemicals, and there is no limit, but also ushered in a more competitive environment. (its competing products have been suppressed, which are competing products, their own look)
From the analysis of market structure, due to the limitations of traditional Chinese medicine injections at the grassroots level, then or will be given to other varieties, especially oral drugs to market opportunities. Oral varieties of hypertension and diabetes in grading treatment under the background of access to a large number of policy support, whether it is basic medication list and rank hospital open connection, or long prescription of good policy, is the so-called bird cage??, structural adjustment is also a reshuffle, the majority of the relevant manufacturers should seize the opportunity to grasp the related basic market.
To look at the market adjustment from the macro policy, research and development, from production to drug registration, access, purchase, use, the whole process of settlement and reimbursement policies to sort out, it is not difficult to see what is to be supported, which is to be suppressed.
Policy support: innovative drugs, children, gynecology, major disease treatment varieties (anti-tumor, cardiovascular and cerebrovascular diseases, diabetes, etc.)
Policy: the excessive use of medical insurance funds, non treatment of nature, the effect is not clear or no evidence (or literature data) support varieties
